Citrate and renal calculi

An update

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Citrate is an inhibitor of the crystallization of stone-forming calcium salts. Hypocitraturia, frequently encountered in patients with nephrolithiasis, is therefore an important risk factor for stone formation. Potassium citrate provides physiological and physicochemical correction and inhibits new stone formation, not only in hypocitraturic calcium nephrolithiasis but also in uric acid nephrolithiasis. Inhibition of stone recurrence has now been validated by a randomized trial. Ongoing research has disclosed additional causes of hypocitraturia (sodium excess, low intestinal alkali absorption, but not primary citrate malabsorption). Moreover, new insights on potassium citrate action have been shown, notably that some of absorbed citrate escapes oxidation and contributes to the citraturic response, that ingestion with a meal does not sacrifice physiological or physicochemical action, that orange juice mimics but does not completely duplicate its action, that potassium citrate may have a beneficial bone-sparing effect, that it may reduce stone fragments following ESWL, and that danger of aluminum toxicity is not great in subjects with functioning kidneys. Finally, the research on potassium citrate has led to two promising products, calcium citrate as an optimum calcium supplement and potassium-magnesium citrate which may be superior to potassium citrate in the management of stone disease.

Original languageEnglish (US)
Pages (from-to)371-377
Number of pages7
JournalMineral and Electrolyte Metabolism
Volume20
Issue number6
StatePublished - 1995

Fingerprint

Potassium Citrate
Kidney Calculi
Citric Acid
Nephrolithiasis
Calcium
Calcium Citrate
Intestinal Absorption
Alkalies
Disease Management
Crystallization
Uric Acid
Aluminum
Research
Toxicity
Meals
Bone
Salts
Eating
Sodium
Kidney

Keywords

  • Alkali
  • Citrate
  • Hypocitraturia
  • Potassium citrate
  • Renal calculi

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Citrate and renal calculi : An update. / Pak, C. Y C.

In: Mineral and Electrolyte Metabolism, Vol. 20, No. 6, 1995, p. 371-377.

Research output: Contribution to journalArticle

@article{8d6c2e1729ca486d84163186e029a961,
title = "Citrate and renal calculi: An update",
abstract = "Citrate is an inhibitor of the crystallization of stone-forming calcium salts. Hypocitraturia, frequently encountered in patients with nephrolithiasis, is therefore an important risk factor for stone formation. Potassium citrate provides physiological and physicochemical correction and inhibits new stone formation, not only in hypocitraturic calcium nephrolithiasis but also in uric acid nephrolithiasis. Inhibition of stone recurrence has now been validated by a randomized trial. Ongoing research has disclosed additional causes of hypocitraturia (sodium excess, low intestinal alkali absorption, but not primary citrate malabsorption). Moreover, new insights on potassium citrate action have been shown, notably that some of absorbed citrate escapes oxidation and contributes to the citraturic response, that ingestion with a meal does not sacrifice physiological or physicochemical action, that orange juice mimics but does not completely duplicate its action, that potassium citrate may have a beneficial bone-sparing effect, that it may reduce stone fragments following ESWL, and that danger of aluminum toxicity is not great in subjects with functioning kidneys. Finally, the research on potassium citrate has led to two promising products, calcium citrate as an optimum calcium supplement and potassium-magnesium citrate which may be superior to potassium citrate in the management of stone disease.",
keywords = "Alkali, Citrate, Hypocitraturia, Potassium citrate, Renal calculi",
author = "Pak, {C. Y C}",
year = "1995",
language = "English (US)",
volume = "20",
pages = "371--377",
journal = "Mineral and Electrolyte Metabolism",
issn = "0378-0392",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Citrate and renal calculi

T2 - An update

AU - Pak, C. Y C

PY - 1995

Y1 - 1995

N2 - Citrate is an inhibitor of the crystallization of stone-forming calcium salts. Hypocitraturia, frequently encountered in patients with nephrolithiasis, is therefore an important risk factor for stone formation. Potassium citrate provides physiological and physicochemical correction and inhibits new stone formation, not only in hypocitraturic calcium nephrolithiasis but also in uric acid nephrolithiasis. Inhibition of stone recurrence has now been validated by a randomized trial. Ongoing research has disclosed additional causes of hypocitraturia (sodium excess, low intestinal alkali absorption, but not primary citrate malabsorption). Moreover, new insights on potassium citrate action have been shown, notably that some of absorbed citrate escapes oxidation and contributes to the citraturic response, that ingestion with a meal does not sacrifice physiological or physicochemical action, that orange juice mimics but does not completely duplicate its action, that potassium citrate may have a beneficial bone-sparing effect, that it may reduce stone fragments following ESWL, and that danger of aluminum toxicity is not great in subjects with functioning kidneys. Finally, the research on potassium citrate has led to two promising products, calcium citrate as an optimum calcium supplement and potassium-magnesium citrate which may be superior to potassium citrate in the management of stone disease.

AB - Citrate is an inhibitor of the crystallization of stone-forming calcium salts. Hypocitraturia, frequently encountered in patients with nephrolithiasis, is therefore an important risk factor for stone formation. Potassium citrate provides physiological and physicochemical correction and inhibits new stone formation, not only in hypocitraturic calcium nephrolithiasis but also in uric acid nephrolithiasis. Inhibition of stone recurrence has now been validated by a randomized trial. Ongoing research has disclosed additional causes of hypocitraturia (sodium excess, low intestinal alkali absorption, but not primary citrate malabsorption). Moreover, new insights on potassium citrate action have been shown, notably that some of absorbed citrate escapes oxidation and contributes to the citraturic response, that ingestion with a meal does not sacrifice physiological or physicochemical action, that orange juice mimics but does not completely duplicate its action, that potassium citrate may have a beneficial bone-sparing effect, that it may reduce stone fragments following ESWL, and that danger of aluminum toxicity is not great in subjects with functioning kidneys. Finally, the research on potassium citrate has led to two promising products, calcium citrate as an optimum calcium supplement and potassium-magnesium citrate which may be superior to potassium citrate in the management of stone disease.

KW - Alkali

KW - Citrate

KW - Hypocitraturia

KW - Potassium citrate

KW - Renal calculi

UR - http://www.scopus.com/inward/record.url?scp=0028897745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028897745&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 371

EP - 377

JO - Mineral and Electrolyte Metabolism

JF - Mineral and Electrolyte Metabolism

SN - 0378-0392

IS - 6

ER -